DK0964697T3 - Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen - Google Patents

Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen

Info

Publication number
DK0964697T3
DK0964697T3 DK97948102T DK97948102T DK0964697T3 DK 0964697 T3 DK0964697 T3 DK 0964697T3 DK 97948102 T DK97948102 T DK 97948102T DK 97948102 T DK97948102 T DK 97948102T DK 0964697 T3 DK0964697 T3 DK 0964697T3
Authority
DK
Denmark
Prior art keywords
antigens
rma
gene
expressed
cells transfected
Prior art date
Application number
DK97948102T
Other languages
English (en)
Inventor
Elisabeth Wolpert
Klas Kaerre
Max Pettersson
Johan Sandberg
Original Assignee
Accuro Immunology Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accuro Immunology Ab filed Critical Accuro Immunology Ab
Application granted granted Critical
Publication of DK0964697T3 publication Critical patent/DK0964697T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK97948102T 1996-12-12 1997-12-12 Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen DK0964697T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604581A SE9604581D0 (sv) 1996-12-12 1996-12-12 An agent against cancer and virus infections
PCT/SE1997/002094 WO1998025645A1 (en) 1996-12-12 1997-12-12 Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene

Publications (1)

Publication Number Publication Date
DK0964697T3 true DK0964697T3 (da) 2003-04-22

Family

ID=20404956

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97948102T DK0964697T3 (da) 1996-12-12 1997-12-12 Terapeutiske anvendelser af antigener eller epitoper knyttet til forringet cellulær peptidprocessering, f.eks. eksprimeret på RMA-S-celler transficeret med et B7-1-gen

Country Status (12)

Country Link
US (1) US20030087846A1 (da)
EP (1) EP0964697B1 (da)
JP (1) JP2001517208A (da)
AT (1) ATE234628T1 (da)
AU (1) AU5423898A (da)
CA (1) CA2274837A1 (da)
DE (1) DE69720065T2 (da)
DK (1) DK0964697T3 (da)
ES (1) ES2193408T3 (da)
PT (1) PT964697E (da)
SE (1) SE9604581D0 (da)
WO (1) WO1998025645A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524601A (ja) * 2000-09-15 2005-08-18 ザ スクリップス リサーチ インスティテュート 抗体による過酸化水素およびスーパーオキシド生成に関する方法および組成物
EP1994406A1 (en) * 2006-03-16 2008-11-26 Leiden University Medical Center Methods for identifying t-cell epitopes associated with impaired peptide processing and applications of the identified epitopes
US20100092435A1 (en) * 2006-12-07 2010-04-15 Emmanuel Jacques Henri Joseph Wiertz Use of a varicellovirus tap-inhibitor for the induction of tumor-or virus-specific immunity against teipp
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
WO2009008713A1 (en) * 2007-07-09 2009-01-15 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce Tap-inhibitors from old world primate 1-herpesviruses and their use
FR2931485B1 (fr) * 2008-05-23 2011-06-17 Centre Nat Rech Scient Vaccin antitumoral comprenant des cellules tumorales modifiees
WO2012089225A1 (en) * 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
US20230044337A1 (en) * 2020-01-29 2023-02-09 University Of Miami Vaccination against antigens induced in pathogen-infected cells
CN111979243B (zh) * 2020-08-24 2023-05-23 大连大学 利用CRISPR/Cas9系统构建TAP基因缺失的猪T2细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2024458A1 (en) * 1970-05-20 1971-12-02 Hartmann geb. Ungewitter, Philippine, Dr., 8000 München Tumour antigen - modified and potentiated by irradiation
DE2918927A1 (de) * 1979-05-10 1980-11-20 Hans Prof Dr Limburg Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
DE69332921T2 (de) * 1992-10-02 2004-05-19 Bristol-Myers Squibb Co. Hemmung des Tumorzellwachstums durch Verabreichung von B7-transfizierten Zellen
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US6361770B1 (en) * 1994-09-23 2002-03-26 University Of British Columbia Method of enhancing expression of MHC class I molecules bearing endogenous peptides
JPH11511968A (ja) * 1995-08-21 1999-10-19 デューク ユニバーシティ 抗原提示細胞上にて抗原密度を増加させる方法

Also Published As

Publication number Publication date
ATE234628T1 (de) 2003-04-15
PT964697E (pt) 2003-07-31
ES2193408T3 (es) 2003-11-01
DE69720065D1 (de) 2003-04-24
SE9604581D0 (sv) 1996-12-12
AU5423898A (en) 1998-07-03
CA2274837A1 (en) 1998-06-18
WO1998025645A1 (en) 1998-06-18
EP0964697A1 (en) 1999-12-22
JP2001517208A (ja) 2001-10-02
EP0964697B1 (en) 2003-03-19
DE69720065T2 (de) 2003-12-04
US20030087846A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
DK0851927T3 (da) Forbindelser til immunterapi og diagnosticering af tuberkulose
DK0979284T3 (da) Reagenser til vaccination, som fremkalder en CD8 T-celleimmunreaktion
DK0724432T3 (da) Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
NO20075900L (no) Forbindelser for immunterapi og diagnose av tuberkulose og metoder for deres anvendelse
DK1276896T3 (da) Epitop-synkronisering i antigen-præsenterende celler
CY1106350T1 (el) Εμβολιο φυματιωσης
DK1263936T3 (da) andret stamme af den modificerede Vacciniavirus Ankara (MVA)
ATE418562T1 (de) Ctl epitope des epstein-barr virus
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP1071451A4 (en) COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
WO2020157222A8 (en) Inactivated apxia, apxiia and apxiiia toxins
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
DE69327529D1 (de) Immunologisch mit HLA homologe HIV Protein Epitope
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
BR0213554A (pt) Timosina para aumento da imunização genética
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis